Current Report Filing (8-k)
August 07 2018 - 4:27PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): August 3, 2018
AMPIO
PHARMACEUTICALS, INC.
(Exact name of registrant as specified
in Charter)
Delaware
|
|
001-35182
|
|
26-0179592
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File No.)
|
|
(IRS Employer
Identification No.)
|
373 Inverness Parkway, Suite 200
Englewood, Colorado 80112
(Address of principal executive offices,
including zip code)
(720) 437-6500
(Registrant’s telephone number,
including area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act
of 1934.
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 8.01. Other Events.
As previously reported, Ampio Pharmaceuticals,
Inc. (the “Company”) met with the U.S. Food and Drug Administration (the “FDA”) in July 2018 to continue
their discussions on the BLA submission being prepared for Ampion
™
as a treatment of the signs and symptoms of
severe (KL 4) osteoarthritis of the knee (OAK) and received a letter from the FDA with respect thereto. Accordingly, the Company
is filing this information with this Current Report on Form 8-K for the purpose of updating the description of certain aspects
of its business from the disclosure contained in the Company’s prior filings with the SEC, including the Company’s
most recent Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on March 6, 2018. The updated disclosures
are filed herewith as Exhibit 99.1 and are incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AMPIO PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Thomas E. Chilcott, III
|
|
|
|
Thomas E. Chilcott, III
|
|
|
|
Chief Financial Officer
|
|
Dated: August 7, 2018
Ampio Pharmaceuticals (AMEX:AMPE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ampio Pharmaceuticals (AMEX:AMPE)
Historical Stock Chart
From Jul 2023 to Jul 2024